Literature DB >> 35378016

Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: COMMENTARY.

Ali K Abu-Alfa1,2.   

Abstract

Entities:  

Keywords:  chronic kidney disease; gadolinium; magnetic resonance imaging; nephrogenic systemic fibrosis

Mesh：

Substances：

Year:  2020        PMID： 35378016      PMCID： PMC8785741          DOI： 10.34067/KID.0006002020

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  13 in total

1.  Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations.

Authors:  Michael Girardi; Jonathan Kay; Dirk M Elston; Philip E Leboit; Ali Abu-Alfa; Shawn E Cowper
Journal:  J Am Acad Dermatol       Date:  2011-07-02       Impact factor: 11.527

2.  Use of Gadolinium-Based Contrast Agents in Kidney Disease Patients: Time for Change.

Authors:  Ali K Abu-Alfa
Journal:  Am J Kidney Dis       Date:  2020-04-10       Impact factor: 8.860

3.  Risk of Nephrogenic Systemic Fibrosis in Stage 4 and 5 Chronic Kidney Disease Following Group II Gadolinium-based Contrast Agent Administration: Subanalysis by Chronic Kidney Disease Stage.

Authors:  Prasad R Shankar; Matthew S Davenport
Journal:  Radiology       Date:  2020-08-18       Impact factor: 11.105

4.  Risk for Nephrogenic Systemic Fibrosis After Exposure to Newer Gadolinium Agents: A Systematic Review.

Authors:  Joseph Lunyera; Dinushika Mohottige; Anastasia-Stefania Alexopoulos; Hilary Campbell; C Blake Cameron; Nicole Sagalla; Timothy J Amrhein; Matthew J Crowley; Jessica R Dietch; Adelaide M Gordon; Andrzej S Kosinski; Sarah Cantrell; John W Williams; Jennifer M Gierisch; Belinda Ear; Karen M Goldstein
Journal:  Ann Intern Med       Date:  2020-06-23       Impact factor: 25.391

Review 5.  Nephrogenic systemic fibrosis and gadolinium-based contrast agents.

Authors:  Ali K Abu-Alfa
Journal:  Adv Chronic Kidney Dis       Date:  2011-05       Impact factor: 3.620

6.  Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.

Authors:  Sean A Woolen; Prasad R Shankar; Joel J Gagnier; Mark P MacEachern; Lisa Singer; Matthew S Davenport
Journal:  JAMA Intern Med       Date:  2020-02-01       Impact factor: 21.873

7.  Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: CON.

Authors:  Patrick H Pun; Susan T Crowley
Journal:  Kidney360       Date:  2020-12-03

Review 8.  Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review.

Authors:  Michael R Rudnick; Ihab M Wahba; Amanda K Leonberg-Yoo; Dana Miskulin; Harold I Litt
Journal:  Am J Kidney Dis       Date:  2020-08-27       Impact factor: 8.860

Review 9.  Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates.

Authors:  Robert J McDonald; Deborah Levine; Jeffrey Weinreb; Emanuel Kanal; Matthew S Davenport; James H Ellis; Paula M Jacobs; Robert E Lenkinski; Kenneth R Maravilla; Martin R Prince; Howard A Rowley; Michael F Tweedle; Herbert Y Kressel
Journal:  Radiology       Date:  2018-09-11       Impact factor: 11.105

10.  Late Onset Nephrogenic Systemic Fibrosis in a Patient with Stage 3 Chronic Kidney Disease: a Case Report.

Authors:  Yu Jeong Lim; Jisun Bang; Youngsun Ko; Hyun Min Seo; Woon Yong Jung; Joo Hark Yi; Sang Woong Han; Mi Yeon Yu
Journal:  J Korean Med Sci       Date:  2020-09-07       Impact factor: 2.153
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.